MHC peptide complexes and uses thereof in infectious diseases

US10336808B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10336808-B2
Application numberUS-201213482472-A
CountryUS
Kind codeB2
Filing dateMay 29, 2012
Priority dateMar 26, 2007
Publication dateJul 2, 2019
Grant dateJul 2, 2019

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Novel compounds carrying ligands capable of binding to counter receptors on relevant target cells are disclosed. The compounds possess a number of advantageous features, rendering them very suitable for a wide range of applications, including use as detection systems, detection of relevant target cells as well as a number of other methods. In particular, novel MHC complexes comprising one or more MHC molecules are disclosed. The affinity and specificity of the MHC-peptide complexes are surprisingly high. The possibility of presenting to the target cells a plurality of MHC-peptide complexes makes the MHC complexes according to the present invention an extremely powerful tool e.g. in the field of therapy and diagnosis. The invention generally relates to the field of therapy, including therapeutic methods and therapeutic compositions. Also comprised by the present invention is the sample-mounted use of MHC complexes and MHC multimers.

First claim

Opening claim text (preview).

The invention claimed is: 1. An isolated MHC multimer comprising (a-b-P) n , wherein n>1, wherein a and b together form a functional MHC protein which is bound to the peptide P, wherein (a-b-P) is the MHC peptide complex formed when the peptide P is bound to the functional MHC protein, wherein each MHC peptide complex of the MHC multimer is associated with one or more multimerization domains selected from the group consisting of scaffolds, carriers, optionally substituted organic molecules, membranes, liposomes or micelles, polymers, polysaccharides, dextran moieties, IgG domains, coiled-coil polypeptide structures, DNA duplexes, nucleic acid duplexes, PNA-PNA, PNA-DNA, DNA-RNA, avidins, streptavidins, antibodies, small organic molecules, proteins, a solid support, and biological polymers, with the proviso that the one or more multimerization domains is not a cell, wherein each MHC protein is an MHC class I molecule encoded by an HLA-A*02 allele, and wherein in at least one MHC peptide complex, the sequence of P originates from a Borrelia OspC antigen, is capable of binding said MHC class I molecule encoded by an HLA-A*02 allele, and is selected from the group consisting of SEQ ID NOS:49735, 49739, 49779, 49795, 49921, and 49937. 2. The isolated MHC multimer according to claim 1 , wherein n is in the range from 8 to 25. 3. The isolated MHC multimer according to claim 1 , wherein n>10. 4. The isolated MHC multimer according to claim 1 , wherein the MHC multimer comprises one or more covalently or non-covalently attached labels, and wherein said one or more labels can be selected from the group consisting of fluorescent labels, fluorophores, enzymes, radioisotopes, chemiluminescent labels, dyes, bioluminescent labels, metal particles, haptens, polymers, and antibodies. 5. A composition comprising a plurality of MHC multimers according to claim 1 and a carrier, wherein the MHC multimers are identical. 6. A composition comprising a plurality of MHC multimers according to claim 1 and a carrier, wherein the MHC multimers are different. 7. A kit comprising a MHC multimer according to claim 1 , a positive control, and/or instructions for use. 8. The isolated MHC multimer according to claim 1 , wherein the HLA*02 allele is selected from the group consisting of HLA-A*0201, HLA-A*0202, HLA-A*0203, HLA-A*0206, HLA-A*0211, HLA-A*0212, HLA-A*0216, HLA-A*0217, HLA-A*0219, and HLA-A*0250.

Assignees

Inventors

Classifications

  • Antivirals · CPC title

  • Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

  • Protozoa · CPC title

  • not provided for elsewhere, e.g. cells, viruses, ghosts, red blood cells, virus capsides · CPC title

  • HLA or MHC typing · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10336808B2 cover?
Novel compounds carrying ligands capable of binding to counter receptors on relevant target cells are disclosed. The compounds possess a number of advantageous features, rendering them very suitable for a wide range of applications, including use as detection systems, detection of relevant target cells as well as a number of other methods. In particular, novel MHC complexes comprising one or mo…
Who is the assignee on this patent?
Schoeller Joegen, Pedersen Henrik, Brix Liselotte, and 1 more
What technology area does this patent fall under?
Primary CPC classification C07K14/70539. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).